{"nctId":"NCT03386474","briefTitle":"Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD","startDateStruct":{"date":"2018-01-15","type":"ACTUAL"},"conditions":["Neovascular Age-related Macular Degeneration"],"count":151,"armGroups":[{"label":"Brolucizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Brolucizumab 6 mg"]},{"label":"Aflibercept","type":"OTHER","interventionNames":["Drug: Aflibercept 2 mg"]}],"interventions":[{"name":"Brolucizumab 6 mg","otherNames":["RTH258"]},{"name":"Aflibercept 2 mg","otherNames":["EYELEA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Sign written informed consent\n* Completed the core study, CRTH258A2301, also known as CRTH258-C002 as defined by assessments at Visit 26/Week 96 within â‰¤12 weeks of the baseline.\n\nExclusion Criteria:\n\n* Patient discontinued the treatment or the core study prematurely at any time\n* Patient received standard of care treatment for nAMD after completion of the core study\n* Pregnant or nursing women and women of child-bearing potential\n* Stroke or MI (myocardial infarction) within 3 months of the baseline extension visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Ocular and Non-Ocular Treatment Emergent Adverse Events","description":"Number of participants with ocular and non-ocular treatment emergent events with the new formulation brolucizumab 6 mg in this extension trial up to week 24 vs. the corresponding last 6 months of brolucizumab treatment in the Core trial \\>= 2%. Safety assessment of the new formulation brolucizumab 6 mg was based on a within-patient comparison with the last 6 months of corresponding Core safety data. Missing brolucizumab data were imputed using last observation carried forward (LOCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Change of Loss in BCVA of 15 Letters or More From Extension Baseline at Each Post-baseline Visit","description":"Best-corrected visual acuity for the study eye was tested at all study visits in a sitting position using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing protocol at an initial testing distance of 4 meters. Outcome measure was prespecified for brolucizumab arm only. Neither patient selection process nor expected sample sizes supported a valid comparison between aflibercept and brolucizumab. The aflibercept arm was included only to maintain the masking in the extension trial. Data presented descriptively for only brolucizumab in line with study objective. No formal hypothesis testing was planned. Missing brolucizumab data were imputed using last observation carried forward (LOCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in BCVA From Extension Baseline at Each Post-baseline Visit","description":"Best-corrected visual acuity for the study eye was tested at all study visits in a sitting position using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing protocol at an initial testing distance of 4 meters. Outcome measure was prespecified for brolucizumab arm only. Neither the patient selection process nor expected sample sizes supported a valid comparison between aflibercept and brolucizumab. The aflibercept arm was included only to maintain the masking in the extension trial. Data was presented descriptively for only brolucizumab in line with the study objective. No formal hypothesis testing was planned. Missing brolucizumab data were imputed using last observation carried forward (LOCF).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"6.26"},{"groupId":"OG001","value":"0.5","spread":"3.81"},{"groupId":"OG002","value":"-0.5","spread":"5.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"6.90"},{"groupId":"OG001","value":"-0.4","spread":"4.29"},{"groupId":"OG002","value":"-1.2","spread":"5.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"7.73"},{"groupId":"OG001","value":"-0.3","spread":"5.17"},{"groupId":"OG002","value":"-1.7","spread":"6.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"8.42"},{"groupId":"OG001","value":"0.8","spread":"5.36"},{"groupId":"OG002","value":"-1.9","spread":"7.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"7.66"},{"groupId":"OG001","value":"0.5","spread":"7.34"},{"groupId":"OG002","value":"-1.8","spread":"7.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"8.17"},{"groupId":"OG001","value":"0.3","spread":"6.79"},{"groupId":"OG002","value":"-1.0","spread":"7.67"}]}]}]},{"type":"SECONDARY","title":"Patients With Positive q12w Treatment Status at Week 20","description":"The estimate for the proportion of patients with a positive q12w treatment status at Week 24 was derived from Kaplan Meier time-to-event analyses for the event 'first q8w-need'. The outcome of the Kaplan-Meier analysis was estimated probability for maintaining on q12w up to the Disease Activity Assessment (DAA) at exWeek 20. Outcome measure was prespecified for brolucizumab arm only. Neither the patient selection process nor expected sample sizes supported a valid comparison between aflibercept and brolucizumab. The aflibercept arm was included only to maintain the masking in the extension trial. Data was presented descriptively for only brolucizumab in line with the study objective. No formal hypothesis testing was planned. Missing brolucizumab data were imputed using last observation carried forward (LOCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null},{"groupId":"OG001","value":"63.1","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Central Sub-Field Thickness (CSFT) From Extension Baseline at Each Post-baseline Visit","description":"Measurement of the central subfield thickness of the retina was assessed using Optical Coherence Tomography (OCT) at each visit for the study eye. Outcome measure was prespecified for brolucizumab arm only. Neither the patient selection process nor expected sample sizes supported a valid comparison between aflibercept and brolucizumab. The aflibercept arm was included only to maintain the masking in the extension trial. Data was presented descriptively for only brolucizumab in line with the study objective. No formal hypothesis testing was planned. Missing brolucizumab data were imputed using last observation carried forward (LOCF).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.2","spread":"39.29"},{"groupId":"OG001","value":"-17.5","spread":"40.76"},{"groupId":"OG002","value":"-18.5","spread":"39.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"25.47"},{"groupId":"OG001","value":"-18.9","spread":"31.74"},{"groupId":"OG002","value":"-11.6","spread":"28.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.9","spread":"43.07"},{"groupId":"OG001","value":"-28.9","spread":"48.80"},{"groupId":"OG002","value":"-22.5","spread":"45.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","spread":"31.94"},{"groupId":"OG001","value":"-11.7","spread":"39.83"},{"groupId":"OG002","value":"-9.4","spread":"35.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"59.04"},{"groupId":"OG001","value":"-15.3","spread":"46.20"},{"groupId":"OG002","value":"-12.3","spread":"53.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.8","spread":"37.67"},{"groupId":"OG001","value":"-24.6","spread":"42.10"},{"groupId":"OG002","value":"-21.8","spread":"39.47"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Positive Anti-drug Antibody (ADA) Status for Brolucuzumab 6 mg in Extension","description":"Positive integrated anti-drug antibodies (ADA) status is defined as induced ADA status with ADA negative at pre-dose and a post-dose titer value of greater than or equal to 30 at any time point or boosted ADA status with ADA positive at pre-dose and a post-dose titer value increase by more than 3-fold (1 dilution) at any time point. Outcome measure was prespecified for brolucizumab arm only. Neither the patient selection process nor expected sample sizes supported a valid comparison between aflibercept and brolucizumab. The aflibercept arm was included only to maintain the masking in the extension trial. Data was presented descriptively for only brolucizumab in line with the study objective. No formal hypothesis testing was planned. Missing brolucizumab data were imputed using last observation carried forward (LOCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":107},"commonTop":["Urinary tract infection","Nasopharyngitis","Neovascular age-related macular degeneration - Fellow eye","Cataract - Fellow eye","Haematuria"]}}}